UCB SA (UCBJY)
USD 98.67
(-2.36%)
USD 98.67
(-2.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.53 Billion EUR | -2.07% |
| 2022 | 15.86 Billion EUR | 11.67% |
| 2021 | 14.21 Billion EUR | 6.69% |
| 2020 | 13.31 Billion EUR | 20.2% |
| 2019 | 11.08 Billion EUR | 5.39% |
| 2018 | 10.51 Billion EUR | 6.02% |
| 2017 | 9.91 Billion EUR | -2.89% |
| 2016 | 10.21 Billion EUR | -6.79% |
| 2015 | 10.95 Billion EUR | 7.96% |
| 2014 | 10.14 Billion EUR | 2.43% |
| 2013 | 9.9 Billion EUR | 5.84% |
| 2012 | 9.36 Billion EUR | 1.98% |
| 2011 | 9.17 Billion EUR | 2.33% |
| 2010 | 8.96 Billion EUR | -1.66% |
| 2009 | 9.12 Billion EUR | -4.24% |
| 2008 | 9.52 Billion EUR | -0.32% |
| 2007 | 9.55 Billion EUR | -8.98% |
| 2006 | 10.49 Billion EUR | 122.56% |
| 2005 | 4.71 Billion EUR | -12.22% |
| 2004 | 5.37 Billion EUR | 73.85% |
| 2003 | 3.09 Billion EUR | 17.93% |
| 2002 | 2.62 Billion EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 15.62 Billion EUR | 0.58% |
| 2024 Q2 | 15.62 Billion EUR | 0.0% |
| 2023 Q3 | 15.53 Billion EUR | 1.02% |
| 2023 Q2 | 15.38 Billion EUR | 0.0% |
| 2023 Q1 | 15.38 Billion EUR | -3.06% |
| 2023 Q4 | 15.53 Billion EUR | 0.0% |
| 2023 FY | 15.53 Billion EUR | -2.07% |
| 2022 Q3 | 15.86 Billion EUR | -2.7% |
| 2022 Q2 | 16.3 Billion EUR | 0.0% |
| 2022 FY | 15.86 Billion EUR | 11.67% |
| 2022 Q1 | 16.3 Billion EUR | 14.76% |
| 2022 Q4 | 15.86 Billion EUR | 0.0% |
| 2021 Q1 | 13.03 Billion EUR | -2.1% |
| 2021 FY | 14.21 Billion EUR | 6.69% |
| 2021 Q4 | 14.21 Billion EUR | 0.0% |
| 2021 Q3 | 14.21 Billion EUR | 8.98% |
| 2021 Q2 | 13.03 Billion EUR | 0.0% |
| 2020 Q3 | 13.31 Billion EUR | 0.77% |
| 2020 FY | 13.31 Billion EUR | 20.2% |
| 2020 Q2 | 13.21 Billion EUR | 0.0% |
| 2020 Q1 | 13.21 Billion EUR | 19.28% |
| 2020 Q4 | 13.31 Billion EUR | 0.0% |
| 2019 Q2 | 10.51 Billion EUR | 0.0% |
| 2019 Q3 | 11.08 Billion EUR | 5.36% |
| 2019 Q4 | 11.08 Billion EUR | 0.0% |
| 2019 FY | 11.08 Billion EUR | 5.39% |
| 2019 Q1 | 10.51 Billion EUR | 0.03% |
| 2018 Q4 | 10.51 Billion EUR | 0.0% |
| 2018 Q3 | 10.51 Billion EUR | 3.12% |
| 2018 FY | 10.51 Billion EUR | 6.02% |
| 2018 Q1 | 10.19 Billion EUR | 2.81% |
| 2018 Q2 | 10.19 Billion EUR | 0.0% |
| 2017 Q4 | 9.91 Billion EUR | 0.0% |
| 2017 Q2 | 9.8 Billion EUR | 0.0% |
| 2017 Q1 | 9.8 Billion EUR | -3.98% |
| 2017 FY | 9.91 Billion EUR | -2.89% |
| 2017 Q3 | 9.91 Billion EUR | 1.13% |
| 2016 Q1 | 10.19 Billion EUR | -6.96% |
| 2016 FY | 10.21 Billion EUR | -6.79% |
| 2016 Q4 | 10.21 Billion EUR | 0.0% |
| 2016 Q3 | 10.21 Billion EUR | 0.19% |
| 2016 Q2 | 10.19 Billion EUR | 0.0% |
| 2015 Q2 | 10.55 Billion EUR | 0.0% |
| 2015 Q1 | 10.55 Billion EUR | 4.05% |
| 2015 FY | 10.95 Billion EUR | 7.96% |
| 2015 Q4 | 10.95 Billion EUR | 0.0% |
| 2015 Q3 | 10.95 Billion EUR | 3.76% |
| 2014 Q3 | 10.14 Billion EUR | 4.36% |
| 2014 Q4 | 10.14 Billion EUR | 0.0% |
| 2014 Q2 | 9.72 Billion EUR | 0.0% |
| 2014 Q1 | 9.72 Billion EUR | -1.85% |
| 2014 FY | 10.14 Billion EUR | 2.43% |
| 2013 Q2 | 9.55 Billion EUR | 0.0% |
| 2013 Q4 | 9.9 Billion EUR | 1.51% |
| 2013 FY | 9.9 Billion EUR | 5.84% |
| 2013 Q3 | 9.76 Billion EUR | 2.11% |
| 2013 Q1 | 9.55 Billion EUR | 2.12% |
| 2012 Q2 | 9.37 Billion EUR | 0.0% |
| 2012 Q3 | 9.35 Billion EUR | -0.21% |
| 2012 Q4 | 9.36 Billion EUR | 0.03% |
| 2012 FY | 9.36 Billion EUR | 1.98% |
| 2011 Q4 | 9.17 Billion EUR | 0.0% |
| 2011 Q2 | 8.5 Billion EUR | 0.0% |
| 2011 FY | 9.17 Billion EUR | 2.33% |
| 2010 Q2 | 9.96 Billion EUR | 0.0% |
| 2010 Q4 | 8.96 Billion EUR | 0.0% |
| 2010 FY | 8.96 Billion EUR | -1.66% |
| 2009 Q4 | 9.12 Billion EUR | 0.0% |
| 2009 FY | 9.12 Billion EUR | -4.24% |
| 2008 FY | 9.52 Billion EUR | -0.32% |
| 2007 FY | 9.55 Billion EUR | -8.98% |
| 2006 FY | 10.49 Billion EUR | 122.56% |
| 2005 FY | 4.71 Billion EUR | -12.22% |
| 2004 FY | 5.37 Billion EUR | 73.85% |
| 2003 FY | 3.09 Billion EUR | 17.93% |
| 2002 FY | 2.62 Billion EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Accustem Sciences Inc. | 939.68 Thousand USD | -1653532.212% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -29385.209% |
| Genus plc | 1.02 Billion USD | -1410.254% |
| LadRx Corporation | 2.3 Million USD | -673201.321% |
| Enzolytics Inc. | 361.7 Million USD | -4196.023% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4394202.31% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -51670.864% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3980523.312% |
| Halberd Corporation | 10.13 Thousand USD | -153380612.664% |
| Skye Bioscience, Inc. | 11.94 Million USD | -130037.899% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -39900.515% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -21472987.819% |
| Kadimastem Ltd | 2.3 Million USD | -674312.347% |
| IMV Inc. | 31.33 Million USD | -49491.835% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4065817.101% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -11833.731% |
| Zenith Capital Corp. | 7410.00 USD | -209703003.914% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -3381.669% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -68210250.731% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -215128.701% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3599273.659% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -44071.239% |
| Q BioMed Inc. | 3.51 Million USD | -441911.801% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -793439.337% |
| Biomind Labs Inc. | 73.81 Thousand USD | -21050036.144% |
| SQZ Biotechnologies Company | 107.18 Million USD | -14397.094% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -672683882.684% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -565708.614% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3113684.694% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5947227.932% |
| CSL Limited | 38.02 Billion USD | 59.132% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2478209.41% |
| CytoDyn Inc. | 11.13 Million USD | -139438.434% |
| Ember Therapeutics, Inc. | 184.00 USD | -8445108595.652% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2429174.485% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -32475.154% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| HST Global, Inc. | 1526.00 USD | -1018282993.054% |
| Helix BioMedix, Inc. | 3.02 Million USD | -513571.347% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -20351158.611% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -10868461.676% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -11991.666% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -86907058.837% |
| Affymax, Inc. | 7.44 Million USD | -208673.344% |
| Alpha Cognition Inc. | 2.45 Million USD | -633583.635% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Qrons Inc. | 420.00 USD | -3699761804.762% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -374692.994% |
| AVAX Technologies, Inc. | 7.37 Million USD | -210536.699% |
| ContraFect Corporation | 20.67 Million USD | -75043.866% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4828585.606% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| SYBLEU INC | 330.46 Thousand USD | -4702019.419% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -147133.276% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -468929.391% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1143858.897% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5945248.25% |
| NovAccess Global Inc. | 62.24 Thousand USD | -24962951.022% |
| Marizyme, Inc. | 22.01 Million USD | -70483.452% |
| Mesoblast Limited | 667.9 Million USD | -2226.544% |
| MultiCell Technologies, Inc. | 126.22 USD | -12311044108.525% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1085001.45% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2260164.209% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2016265.533% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | -3257.214% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -596820.094% |
| GB Sciences, Inc. | 103.44 Thousand USD | -15021844.665% |
| argenx SE | 4.54 Billion USD | -242.084% |
| Resverlogix Corp. | 8.11 Million USD | -191384.904% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -827375.664% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -55507.644% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1072410.962% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -173536.505% |
| ONE Bio Corp. | 70.08 Million USD | -22071.489% |
| Genscript Biotech Corporation | 3.38 Billion USD | -358.867% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1674431.581% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1572725.813% |
| Agentix Corp. | 261.39 Thousand USD | -5944611.391% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -106621.768% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -27216420.125% |
| Cell Source, Inc. | 195.17 Thousand USD | -7961636.119% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3233439.414% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4394202.31% |
| Itoco Inc. | 1.4 Million USD | -1109771.492% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -16244398.573% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -14659333.962% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4031072.254% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2814324.4% |
| Rebus Holdings, Inc. | 5000.00 USD | -310779900.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3795250.519% |
| Mobile Lads Corp. | 52.00 USD | -29882692207.692% |
| International Stem Cell Corporation | 5.39 Million USD | -288193.135% |
| Bioxytran, Inc. | 137.63 Thousand USD | -11289660.095% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -103480.696% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -93627.004% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -19669520.253% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1796987.236% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -206618.106% |
| Neutra Corp. | 2851.00 USD | -545036729.183% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -47850.997% |
| PureTech Health plc | 693.97 Million USD | -2139.136% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -192426.684% |
| IXICO plc | 15.84 Million USD | -97975.582% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -187523.762% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -14939.1% |
| CSL Limited | 38.02 Billion USD | 59.132% |
| Cellectis S.A. | 333.99 Million USD | -4552.47% |